However, current clinical features and biomarkers, such as the TNM staging system, Barcelona Clinic Liver Cancer (BCLC) staging system, and serum alpha-fetoprotein (AFP) level, are insufficient for providing accurate prognostic evaluations for HCC patients in clinical practice (8, 9). The gene discussed is AFP; the disease is hepatocellular carcinoma.